Overview Dividends

(IQV) IQVIA Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266C1053

Clinical Research, Analytics, Consulting, Trial Support, Outsourcing

Life Sciences Tools & Services
Market Cap in USD: 37,584m

IPO / Inception: 2013-05-09
Return 12m vs S&P 500: -2.43%

EPS (Earnings per Share)

EPS CAGR: 4.43%
EPS Trend: -29.5%

Last SUE: 0.15
Qual. Beats: 0

Revenue

Rev. CAGR: 3.25%
Rev. Trend: 91.8%

Last SUE: 0.69
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	25.4%
Value at Risk 5%th	39.0%
Relative Tail Risk	-6.75%

Reward TTM
Sharpe Ratio	0.41
Alpha	-3.44
CAGR/Max DD	0.07

Character TTM
Hurst Exponent	0.494
Beta	0.998
Beta Downside	1.088

Drawdowns 3y
Max DD	47.12%
Mean DD	17.30%
Median DD	15.91%

Description: IQV IQVIA Holdings December 17, 2025

IQVIA Holdings Inc. (NYSE:IQV) delivers end-to-end data, analytics, and clinical services to life-science and health-care companies across the Americas, Europe, Africa, and Asia-Pacific, organized into three operating segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Key recent metrics: FY 2023 revenue reached $13.1 billion, up 5 % YoY, driven by a 12 % rise in the Real-World Evidence (RWE) platform and a 9 % increase in contract sales services. The company posted an adjusted operating margin of 13.2 % and generated $1.8 billion of free cash flow, supporting its $2.5 billion backlog of multi-year contracts. Core sector drivers include accelerating pharmaceutical R&D spend (projected CAGR ≈ 7 % through 2028), the industry’s shift toward decentralized clinical trials, and heightened regulator demand for real-world data to inform drug approvals.

For deeper valuation metrics and scenario analysis, you might find ValueRay’s IQV page worth a look.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.28b TTM) > 0 and > 6% of Revenue (6% = 954.2m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 1.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -15.90% (prev -8.88%; Δ -7.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 2.80b > Net Income 1.28b (YES >=105%, WARN >=100%)

Net Debt (13.38b) to EBITDA (3.44b) ratio: 3.89 <= 3.0 (WARN <= 3.5)

Current Ratio 0.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (171.7m) change vs 12m ago -6.79% (target <= -2.0% for YES)

Gross Margin 33.78% (prev 33.42%; Δ 0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 56.89% (prev 56.35%; Δ 0.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.26 (EBITDA TTM 3.44b / Interest Expense TTM 707.0m) >= 6 (WARN >= 3)

Altman Z'' 1.04

(A) -0.09 = (Total Current Assets 5.98b - Total Current Liabilities 8.51b) / Total Assets 28.73b

(B) 0.24 = Retained Earnings (Balance) 6.91b / Total Assets 28.73b

(D) 0.27 = Book Value of Equity 5.99b / Total Liabilities 22.44b

Total Rating: 1.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.34

1. Piotroski 6.50pt

2. FCF Yield 5.18%

3. FCF Margin 16.60%

4. Debt/Equity 2.47

5. Debt/Ebitda 3.89

6. ROIC - WACC (= 1.88)%

7. RoE 21.40%

8. Rev. Trend 91.76%

9. EPS Trend -29.52%

What is the price of IQV shares?

As of December 28, 2025, the stock is trading at USD 226.92 with a total of 306,063 shares traded.
Over the past week, the price has changed by +2.82%, over one month by -2.11%, over three months by +26.38% and over the past year by +13.32%.

Is IQV a buy, sell or hold?

IQVIA Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy IQV.

Strong Buy: 14
Buy: 2
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the IQV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	254	11.9%
Analysts Target Price	254	11.9%
ValueRay Target Price	248.6	9.5%

IQV Fundamental Data Overview December 23, 2025

Market Cap USD = 37.58b (37.58b USD * 1.0 USD.USD)
P/E Trailing = 30.3981
P/E Forward = 16.835
P/S = 2.3631
P/B = 6.1012
P/EG = 0.9359
Beta = 1.369
Revenue TTM = 15.90b USD
EBIT TTM = 2.31b USD
EBITDA TTM = 3.44b USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 2.16b USD (from shortTermDebt, last quarter)
Debt = 15.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 50.96b USD (37.58b + Debt 15.19b - CCE 1.81b)
Interest Coverage Ratio = 3.26 (Ebit TTM 2.31b / Interest Expense TTM 707.0m)
FCF Yield = 5.18% (FCF TTM 2.64b / Enterprise Value 50.96b)
FCF Margin = 16.60% (FCF TTM 2.64b / Revenue TTM 15.90b)
Net Margin = 8.07% (Net Income TTM 1.28b / Revenue TTM 15.90b)
Gross Margin = 33.78% ((Revenue TTM 15.90b - Cost of Revenue TTM 10.53b) / Revenue TTM)
Gross Margin QoQ = 33.49% (prev 32.94%)
Tobins Q-Ratio = 1.77 (Enterprise Value 50.96b / Total Assets 28.73b)
Interest Expense / Debt = 1.24% (Interest Expense 189.0m / Debt 15.19b)
Taxrate = 18.63% (76.0m / 408.0m)
NOPAT = 1.88b (EBIT 2.31b * (1 - 18.63%))
Current Ratio = 0.70 (Total Current Assets 5.98b / Total Current Liabilities 8.51b)
Debt / Equity = 2.47 (Debt 15.19b / totalStockholderEquity, last quarter 6.16b)
Debt / EBITDA = 3.89 (Net Debt 13.38b / EBITDA 3.44b)
Debt / FCF = 5.07 (Net Debt 13.38b / FCF TTM 2.64b)
Total Stockholder Equity = 6.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.47% (Net Income 1.28b / Total Assets 28.73b)
RoE = 21.40% (Net Income TTM 1.28b / Total Stockholder Equity 6.00b)
RoCE = 12.27% (EBIT 2.31b / Capital Employed (Equity 6.00b + L.T.Debt 12.79b))
RoIC = 9.07% (NOPAT 1.88b / Invested Capital 20.69b)
WACC = 7.19% (E(37.58b)/V(52.77b) * Re(9.69%) + D(15.19b)/V(52.77b) * Rd(1.24%) * (1-Tc(0.19)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.48%
[DCF Debug] Terminal Value 73.77% ; FCFE base≈2.37b ; Y1≈2.55b ; Y5≈3.15b
Fair Price DCF = 243.3 (DCF Value 41.43b / Shares Outstanding 170.3m; 5y FCF grow 8.85% → 3.0% )
EPS Correlation: -29.52 | EPS CAGR: 4.43% | SUE: 0.15 | # QB: 0
Revenue Correlation: 91.76 | Revenue CAGR: 3.25% | SUE: 0.69 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.95 | Chg30d=+0.009 | Revisions Net=+2 | Analysts=13
EPS next Year (2026-12-31): EPS=12.94 | Chg30d=+0.015 | Revisions Net=+2 | Growth EPS=+8.8% | Growth Revenue=+5.4%

Additional Sources for IQV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle